The basic helix-loop-helix transcription factor family includes the cytoplasmic receptor and transcription factor known as aryl hydrocarbon receptor (AhR or AHR). Exogenous and endogenous ligands of various types can either activate or inhibit the AhR. When it comes to immunity and tissue homeostasis, AhR plays a crucial role. A variety of structurally different substances, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), can activate AhR.
Indigooids, heme metabolites, eicosanoids, tryptophan derivatives, and equilenin are examples of endogenous ligands. Polycyclic aromatic hydrocarbons, polychlorinated biphenyls, natural substances, and small molecule substances are examples of exogenous ligands. Because AhR ligands differ in their shapes and characteristics, their interactions with AhR have unique biological effects.
Hsp90, AIP, and p23 are examples of chaperone proteins that sequester unliganded AHR in the cytoplasm. AHR moves into the nucleus after ligand binding and forms a heterodimer with ARNT. The aryl hydrocarbon response elements, which are found in the regulatory regions of target genes like CYP1A1, CYP1B1, and TIPARP, are where the AHR-ARNT complex regulates transcription by binding with high affinity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74745 | 3-OH-Kynurenamine | 99362-47-7 | 3-OH-Kynurenamine is a lateral metabolite in the metabolism of Tryptophan. |
|
V51688 | 6,2',4'-Trimethoxyflavone | 720675-74-1 | 6,2',4'-Trimethoxyflavone is a potent aryl hydrocarbon receptor (AHR) antagonist. |
|
V80526 | AHR agonist 4 | AHR agonist 4 (compound 24e) is an agonist of the aryl hydrocarbon receptor AHR and is related to the immune balance of Th17/22 and Treg cells. | |
|
V78602 | AHR antagonist 5 hemimaleate | AHR antagonist 5 hemimaleate is a potent, orally bioactive aryl hydrocarbon receptor (AHR) antagonist (inhibitor) with IC50 of < 0.5 μM. | |
|
V3650 | Benvitimod (Tapinarof) | 79338-84-4 | Benvitimod (Tapinarof; WB1001;GSK2894512) is a naturally occurringaryl hydrocarbon receptor (AhR) agonist (EC50 = 13 nM) approved in China for treatingplaque psoriasis. |
|
V51699 | Benzyl butyl phthalate | 85-68-7 | Butyl phthalate, a member of phthalate esters (PAEs), can cause hemangioma (HA) cells to migrate and increase by upregulating the expression of Zeb1. |
|
V51083 | Benzyl butyl phthalate-d4 | 93951-88-3 | Butyl phthalate, a member of phthalates (PAEs), can cause the migration and body weight of hemangioma (HA) cells by upregulating the expression of Zeb1. |
|
V2129 | Carbidopa | 28860-95-9 | Carbidopa (also known as MK485, MK-485; trade name: Lodosyn; abbreviated as CD), a potent and competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine. |
|
V51696 | Carbidopa-d3 monohydrate | 1276197-58-0 | Carbidopa-d3 (monohydrate) is the deuterated form of carbidopa monohydrate. |
|
V3994 | CAY10465 | 688348-33-6 | CAY 10465, an analog of resveratrol, is a novel, potent, selective and high-affinityAhR (aryl hydrocarbon receptor) agonist, with aKiof 0.2 nM, and shows no effect on estrogen receptor (Ki>100000 nM). |
|
V51693 | Flavipin | 483-53-4 | Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that can induce the expression of Ahr downstream genes in mouse CD4+ T cells and CD11b+ macrophages. |
|
V51692 | Indolokine A5 | 951207-88-8 | Indolokine A5, a catabolite of L-cysteine, is a potent AhR agonist. |
|
V51695 | KYN-101 | 2247950-73-6 | KYN-101 is a potent, selective and orally bioactive AHR inhibitor. |
|
V51694 | Norisoboldine hydrochloride | 5083-84-1 | Norisoboldine HCl is a natural aryl hydrocarbon receptor (AhR) agonist/activator with epidermal activity. |
|
V4036 | PDM2 | 688348-25-6 | PDM-2 (PDM2),a trans-resveratrol analog, is a novel selective, high-affinity aryl hydrocarbon receptor (AhR) antagonist with anKiof 1.2±0.4 nM. |
|
V2919 | YL-109 | 36341-25-0 | YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
